Charles Russell Speechlys advises Kreos Capital on €20 million growth capital facility in Medtech company
Charles Russell Speechlys have advised Kreos Capital on its additional growth capital facility of €20 million in Cellnovo Limited (“Cellnovo”), the wholly-owned subsidiary company of Cellnovo Group SA, a Med Tech company marketing the first mobile, connected, all-in-one diabetes management system, listed on Euronext Paris. This is a follow on facility by Kreos subsequent to its €7 million growth capital facility in 2015 and its €5 million growth capital facility in 2017.
The Charles Russell Speechlys core team comprised Chris Putt (Partner), Rossana Conti (Legal Director), Amelly Kok (Associate) and Dafni Loizou (Associate) from our Corporate Team, and Paul Kay (Partner) from our Banking Team. Foreign counsel who have advised on this transaction are Reinhart Marville Torre (French law).
News & Insights
Charles Russell Speechlys advises Daystar Power Group and founder on $10 million equity stake by Verod Capital Management and Persistent Energy
Daystar Power Group is a pan-African electricity company specialising in the generation of solar energy.
Charles Russell Speechlys advises FPE Capital and members of the management team of Kallidus on its sale
Kallidus is a leading human capital management and e-learning (SaaS) provider.
Focus Antitrust - 20 March 2019
The latest edition of our regular Focus Antitrust update.